Cryo electron microscopy, or Cryo-EM, enables high-resolution screening for small-molecules or biological ligands, particularly for targets that are challenging to crystallize. One area that technology is proving to be a valuable tool for is the development of lipid nanoparticles, which have emerged as important vectors for mRNA and other genetic medicines. Cryo-EM can be used to analyze the size, shape, payload characteristics and other aspects of LNPs. We spoke Tim O’Bryan, director of discovery partnerships and commercial integration for Charles River Labs; and Karl Bertram, co-founder and managing director for ATEM Structural Discovery; about ATEM’s Cryo-EM technology, its incorporation of machine learning, and how it fits in with Charles Rivers’ broader drug discovery offerings.

Ver todos los episodios